Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
Author:
Publisher
BMJ
Subject
Gastroenterology
Reference25 articles.
1. Centers for Disease Control and Prevention. Inflammatory Bowel Disease (IBD). 2014 (2 July 2014). http://www.cdc.gov/ibd/
2. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease;Rubin;Aliment Pharmacol Ther,2014
3. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review;Park;Inflamm Bowel Dis,2011
4. Health insurance paid costs and drivers of costs for patients with Crohn's disease in the United States;Park;Am J Gastroenterol,2016
5. Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease;Wu;Inflamm Bowel Dis,2013
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020;Inflammatory Bowel Diseases;2024-09-11
2. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis;Cureus;2024-06-02
3. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib;Journal of Medical Economics;2024-04-05
4. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan;PharmacoEconomics;2023-03-08
5. Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France;Expert Review of Pharmacoeconomics & Outcomes Research;2023-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3